Mylan Sharpens Injectables Business With Agila Buy For $1.6 Billion
This article was originally published in PharmAsia News
Executive Summary
A stream of highly profitable drug launches in the U.S. by India’s Agila attracted Mylan to make an aggressive bid, leapfrogging it from the bottom 10 rank to a leading position in the injectables space.